For research use only, not for therapeutic use.
YH-306（Cat No.:I038545）is a selective antagonist of the prostaglandin E2 receptor subtype 4 (EP4), which is involved in mediating inflammatory responses and promoting tumor growth. By blocking EP4 signaling, YH-306 inhibits key processes in cancer progression, including cell proliferation, angiogenesis, and immune evasion. It has shown promise in preclinical studies for its potential to treat various cancers and inflammation-related diseases. YH-306’s ability to modulate immune responses also makes it a valuable candidate for cancer immunotherapy, offering a new approach to targeting tumors and managing chronic inflammation.
| Catalog Number | I038545 |
| CAS Number | 1373764-75-0 |
| Synonyms | YH-306; YH 306; YH306; |
| Molecular Formula | C19H18N2O2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | 4°C, protect from light |
| IUPAC Name | 2-(4-hydroxyphenyl)-1-(1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)ethanone |
| InChI | InChI=1S/C19H18N2O2/c22-14-7-5-13(6-8-14)11-19(23)21-10-9-16-15-3-1-2-4-17(15)20-18(16)12-21/h1-8,20,22H,9-12H2 |
| InChIKey | WFTJZQLEQGPZBC-UHFFFAOYSA-N |
| SMILES | C1CN(CC2=C1C3=CC=CC=C3N2)C(=O)CC4=CC=C(C=C4)O |
| Reference | 1: Dai F, Chen Y, Huang L, Wang J, Zhang T, Li J, Tong W, Liu M, Yi Z. A novel synthetic small molecule YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. J Cell Mol Med. 2015 Feb;19(2):383-95. doi: 10.1111/jcmm.12450. Epub 2014 Oct 29. PubMed PMID: 25351103; PubMed Central PMCID: PMC4407606. |
